LLY241018P927500
- 10.36
- -0.29-2.72%
Eli Lilly and Co Newsroom
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,158
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Eli Lilly & Co: Buy Rating Justified Despite Short-Term Sales Miss
Eli Lilly Analyst Ratings
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,033
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,101
Eli Lilly Analyst Ratings
Guggenheim Adjusts Eli Lilly and Company Price Target to $884 From $1,030
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,025
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,150
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000